Bicycle Therapeutics (BCYC)
NASDAQ: BCYC
· Real-Time Price · USD
7.39
-0.15 (-1.99%)
At close: Aug 19, 2025, 11:57 AM
-1.99% (1D)
| Bid | 7.34 |
| Market Cap | 511.55M |
| Revenue (ttm) | 25.73M |
| Net Income (ttm) | -203.27M |
| EPS (ttm) | -3.52 |
| PE Ratio (ttm) | -2.1 |
| Forward PE | -1.74 |
| Analyst | Buy |
| Ask | 7.42 |
| Volume | 55,282 |
| Avg. Volume (20D) | 280,590 |
| Open | 7.50 |
| Previous Close | 7.54 |
| Day's Range | 7.34 - 7.50 |
| 52-Week Range | 6.10 - 28.67 |
| Beta | 1.45 |
About BCYC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCYC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCYC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Bicycle Therapeutics is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+13.9%
Bicycle Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
11 months ago
-7.59%
Bicycle Therapeutics shares are trading lower. The company announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate zelenectide pevedotin in metastatic urothelial cancer; BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist BT7480 in advanced solid tumors.
1 week ago · fool.com
Bicycle (BCYC) Q2 Revenue Falls 69%Bicycle (BCYC) Q2 Revenue Falls 69%
2 months ago · businesswire.com
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual MeetingCAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicy...